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ScienceDirectThe series of events underlying the pathogenesis of Alzheimer
disease (AD) in unknown. The most widely accepted
hypothesis is called the amyloid cascade, based on the
observation that the brains of AD patients contain high levels of
extracellular plaques, composed mainly of b-amyloid (Ab), and
intracellular tangles, composed of hyperphosphorylated forms
of the microtubule-associated protein tau. However, AD is also
characterized by other features, including aberrant cholesterol,
phospholipid, and calcium metabolism, and mitochondrial
dysfunction, all ostensibly unrelated to plaque and tangle
formation. Notably, these ‘other’ aspects of AD pathology are
functions related to mitochondria-associated ER membranes
(MAM), a subdomain of the endoplasmic reticulum (ER) that is
apposed to, and communicates with, mitochondria. Given the
potential relationship between MAM and AD, we explored the
possibility that perturbed MAM function might play a role in AD
pathogenesis. We found that g-secretase activity, which
processes the amyloid precursor protein to generate Ab, is
located predominantly in the MAM, and that ER–mitochondrial
apposition and MAM function are increased significantly in cells
from AD patients. These observations may help explain not only
the aberrant Ab production, but also many of the ‘other’
biochemical and morphological features of the disease. Based
on these, and other, data we propose that AD is fundamentally
a disorder of ER–mitochondrial hyperconnectivity.
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Alzheimer disease
Alzheimer disease (AD) is the most common neurodegen-
erative dementia of aging [1]. It is defined operationally asCurrent Opinion in Genetics & Development 2016, 38:90–96 a disorder in which there is an accumulation of extracellu-
lar neuritic plaques and intracellular tangles in the brain
[1]. The plaques are composed of numerous proteins [2,3],
but foremost among them is b-amyloid (Ab). The tangles
are more homogeneous and consist mainly of aggregates of
hyperphosphorylated forms of the microtubule-associated
protein tau [1,4].
The familial form of AD (FAD), which affects 1% of all
patients, is inherited as an autosomal-dominant trait, and
is caused by mutations in one of three genes: presenilin-1
(PS1), presenilin-2 (PS2), and the amyloid precursor pro-
tein (APP). PS1 and PS2 are aspartyl proteases that are the
enzymatically active components of the g-secretase com-
plex that, together with b-secretase (BACE1), processes
APP to produce Ab, thereby likely explaining the deposi-
tion of amyloid in these patients (Figure 1). In sporadic AD
(SAD), which comprises the vast majority of cases, the
mechanistic connection to amyloid deposition is far less
clear. However, individuals harboring the e4 allele of
apolipoprotein E (hereinafter ApoE4), which is a compo-
nent of lipoproteins that are involved in intercellular
cholesterol trafficking, are at significantly higher risk for
developing AD than those harboring the more common e3
allele [5,6]; the reason for this elevated risk is unknown.
The amyloid cascade hypothesis
The pathogenetic mechanism that causes AD is un-
known, but the discovery that mutations in presenilins
(which cleave APP) and in APP itself (which is a substrate
of the presenilin-containing g-secretase complex) in FAD
patients gave rise to the most dominant, and commonly
accepted, hypothesis to explain pathogenicity in both
FAD and SAD, namely the ‘amyloid cascade’ [7]. The
hypothesis proposes that the disease arises when APP is
cleaved by BACE1 to produce a 99-aa C-terminal frag-
ment (C99), which is then cleaved by g-secretase to
produce a 50-aa APP intracellular domain (AICD)
and a range of Ab fragments that average 40-aa in
length in normal individuals but 42-aa in AD
(Figure 1), with a concomitant increase in the ratio of
Ab42:Ab40. As opposed to Ab40, Ab42 is fibrillogenic and
accumulates in the plaques. This amyloid is toxic to cells,
and the resulting stress promotes tau hyperphosphoryla-
tion, leading to the tangles, with both the extraneuritic
plaques and the intraneuronal tangles conspiring to cause
the disease by promoting cell death [4,7] (Figure 2).
The amyloid cascade hypothesis is compelling, not only
because it unites findings from many different approacheswww.sciencedirect.com
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Amyloidogenic processing of APP. Consecutive cleavages of APP, a
membrane-tethered protein (shaded box), by BACE1 (to produce C99
and soluble APPb) and g-secretase (containing PS1 or PS2) generate
Ab and the APP intracellular domain (AICD).
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The amyloid cascade hypothesis. Aberrant APP processing gives rise
to plaques and then tangles (reproduced from [71], with permission).
See text for details.
www.sciencedirect.com to the disease, but also because it explains why mutations
in both the g-secretase enzyme (i.e. PS1, PS2) and its
substrate (i.e. APP) cause FAD. However, besides the
obvious problem of the lack of mutations in these three
proteins in SAD, a nagging concern has been that the
amyloid cascade does not address a number of issues that
are central to both understanding and explaining AD
pathogenesis. In particular, AD is associated with other
features that have received less attention in the field,
because there is no unifying conceptual framework within
the amyloid cascade that would explain their occurrence
[8,9]. These include altered cholesterol [10], fatty acid
[11], glucose [12,13], and phospholipid [14] metabolism,
aberrant calcium homeostasis [15], and mitochondrial
dysfunction [16] (Figure 3).
Mitochondria-associated ER membranes
As a group focused predominantly on human mitochondrial
biology, function, and disease [17], we noticed that there
was a common theme that had the potential to unite these
disparate features of AD under a single rubric, namely
mitochondria-associated ER membranes (MAM). MAM
is a subdomain of the endoplasmic reticulum (ER) that
communicates with mitochondria, both physically and bio-
chemically [18,19,20,21]. Among the proteins enriched
in or localized to the MAM are those involved in lipid
metabolism (e.g. phosphatidylserine synthase [22,23]), in
cholesterol metabolism (e.g. acyl-CoA:cholesterol acyl-
transferase 1 [ACAT1] [21] and steroidogenic acute regu-
latory protein [24]), in calcium homeostasis (e.g. IP3
receptors [25,26]), in lipid transfer between the ER and
mitochondria (e.g. fatty acid transfer protein 4 [27]), and in
the maintenance of mitochondrial function (e.g. voltage-
dependent anion channel 2 [24]) and morphology (e.g.
dynamin-related protein 1 [28]); notably, these MAM-
related functions are the very ones that are perturbed in
AD. In addition, other proteins stabilize and regulate the
interaction of ER and mitochondria, including mitofusin
2 [29] and phosphofurin acidic cluster sorting protein
2 [30], but the exact ‘tethering’ mechanism is unknown.
Based on the supposition that MAM might play a role in
AD pathogenesis, we and others found that PS1 and PS2
[31,32], and g-secretase activity itself [31,33], are
localized predominantly at the MAM. This localization
could account for the reported localizations of Ab [34] and
PS1 [35] to mitochondria. In addition, the finding that
MAM is an intracellular lipid raft [36,37] supports the
view that the lipid rafts in which PS1 and g-secretase
activity are known to reside [38] are located not only at
the plasma membrane [31,39] but also intracellularly, at
the MAM [36,37].
MAM function is perturbed in AD
Given the enrichment of the presenilins and of g-secre-
tase activity in the MAM, we explored the possibility that
MAM function might be altered in AD, minimally inCurrent Opinion in Genetics & Development 2016, 38:90–96
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Other features of Alzheimer disease. Besides plaques and tangles [71], AD is also characterized by perturbations in calcium homeostasis,
cholesterol metabolism, phospholipid metabolism, and dynamics and function of mitochondria [72].presenilin-mutant cells and in cells from FAD patients
harboring mutations in presenilin (FADPS). Some AD-
relevant aspects of MAM behavior, such as calcium
metabolism and mitochondrial function, have been stud-
ied in great detail by others, albeit not in the context of
MAM. For example, there is a rather large literature
showing that calcium trafficking, which is fundamentally
a MAM-mediated process [19,40,41], is altered in AD
patients [42–44], in patient fibroblasts [45–47], and in
PS1-mutant mice [48]. Similarly, mitochondrial function,
including bioenergetics and mitochondrial dynamics,
have also been shown to be altered significantly in AD
[46,49–55]. Thus, the changes found in calcium and
mitochondrial function in AD are almost certainly due
to perturbed ER–mitochondrial communication at the
MAM. We therefore decided to study other aspects of
MAM function that are relevant to AD but that have
received less attention, focusing on phospholipid [14] and
cholesterol [10] homeostasis in mouse embryonic fibro-
blasts (MEFs) lacking presenilins, in PS1-knockdown
MEFs, and in fibroblasts from FADPS patients.
In broad view, phospholipid synthesis takes place in two
compartments: the cytoplasm (via the ‘Kennedy’ path-
way) and the MAM [56]. In the MAM, phosphatidylserineCurrent Opinion in Genetics & Development 2016, 38:90–96 (PtdSer) translocates from the ER to mitochondria, where
it is converted to phosphatidylethanolamine (PtdEtn);
PtdEtn then travels back to the ER to be converted into
phosphatidylcholine [57]. We found that PtdSer and
PtdEtn synthesis and transport were increased signifi-
cantly in PS-mutant cells and FADPS fibroblasts [36],
indicating upregulated ER–mitochondrial cross-talk in
those cells. These results are consistent with, and may
help explain, the altered phospholipid profiles seen in
FAD patients [14].
In addition to phospholipid synthesis and transport, we
measured another MAM-localized activity [21,36],
namely, the intracellular conversion by ACAT1 (gene
SOAT1) of free cholesterol to cholesteryl esters (CE) that
are then stored in cytoplasmic lipid droplets [58]. We
found significantly more CE in the PS-mutant and FADPS
fibroblasts than in the corresponding control cells [36].
Notably, the increase in CE in these cells was parallelled
by a concomitant increase in cytoplasmic neutral lipid
droplets (containing CE) [36], indicating that these cells
were trying to maintain cholesterol homeostasis [58] by
reducing excess free cholesterol that would otherwise be
toxic to the cells [59]. We note that patients with AD have
elevated circulating cholesterol [10] and increased lipidwww.sciencedirect.com
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appears to be required for the production of Ab
[58,62], but the reasons for these observations are cur-
rently unknown.
Remarkably, these findings on altered MAM-mediated
phospholipid and cholesterol homeostasis and on in-
creased ER–mitochondrial apposition were not limited
to presenilin-mutant cells. We obtained essentially iden-
tical results in fibroblasts from FAD patients with muta-
tions in APP, and even more notably, in fibroblasts fromFigure 4
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www.sciencedirect.com patients with SAD [36]. The fact that lipid dyshomeos-
tasis and altered MAM morphology could be observed in
AD cells in which the presenilin and/or APP genes are
normal implies that upregulated ER–mitochondrial com-
munication and dysregulated MAM function are likely to
be a general property of cells from essentially all AD
patients, and that altered MAM behavior is a pathoge-
netic event upstream of plaque and tangle formation.
The idea that perturbed MAM behavior is a precipitating
event in AD was reinforced by recent work on theD (e.g. ApoE4)
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 AD is upregulated ER–mitochondria communication at the MAM. This
 Ab42:Ab40 ratio; the plaques and tangles arise as a downstream result
ult of a derangement in specific biochemical pathways brought on by
ase of SAD).
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function [63]. Specifically, human fibroblasts and neuro-
nal-like SH-SY5Y cells treated with astrocyte-condi-
tioned media (ACM) from knock-in mice expressing
human ApoE4 upregulated MAM function to a signifi-
cantly greater extent than did ACM from ApoE3 knock-in
mice [63]. Moreover, the effects of ApoE4 were appar-
ently due to its role as a component of lipoproteins, not as
the free, unlipidated protein [63], implying that its
effects on MAM were related to its function in lipopro-
tein-mediated cholesterol trafficking and metabolism. We
note that ApoE4 is recycled less efficiently than is ApoE3
[64,65], thereby causing cholesterol to accumulate in
endosomes and lysosomes, which can then traffic to the
ER [66]. Thus, the increase in CE and lipid droplets seen
in ApoE4-ACM-treated cells may well have reflected a
concomitant increase in cholesterol metabolism at the
MAM. Thus, ApoE4 in SAD cells appears to mimic the
effects of upregulated cholesterol metabolism in FAD
cells, and may help explain, in part, the contribution of
ApoE4 as a risk factor in the disease. This supposition is
also consistent with the identification of allelic variants in
other cholesterol metabolism-related genes as risk factors
in AD [67], including ABCA7 [68], which promotes the
cellular efflux of both phospholipids and cholesterol [69].
The MAM hypothesis
Based on the findings summarized above, we propose that
the pathogenesis of AD is mediated by increased ER–
mitochondrial communication, which in turn alters the
function of proteins that reside at the interface of these
two organelles, both in degree and in kind (Figure 4). The
increase in ER–mitochondrial apposition would be con-
sistent with, and perhaps explain, the increased calcium
trafficking between the two organelles [15,42–44], the
aberrant phospholipid profiles [14], the perturbed choles-
terol homeostasis [10], the changes in mitochondrial func-
tion, morphology, and distribution [16,46,49–55], and the
increased Ab42:Ab40 ratio seen in AD (Figure 4). On this
last point, we believe that the altered ER membrane
topology at the MAM in AD [70] could explain the shift
in the location of the g-secretase cleavage site on APP-C99
away from Ab40 and towards Ab42 [9].
Taken together, our findings support the view that the
functional cause of AD is increased ER–mitochondrial
communication and upregulated MAM function. How-
ever, the biochemical cause of ER–mitochondrial hyper-
connectivity, and its relationship to aberrant APP
processing, are currently unclear. Work to elucidate these
upstream causes of perturbed MAM structure and func-
tion is currently under way.
Acknowledgements
This work was supported by the U.S. National Institutes of Health (K01
AG045335 to EA-G), the U.S. Department of Defense (W911F-15-1-0169 to
EAS), and the J. Willard and Alice S. Marriott Foundation (to EAS).Current Opinion in Genetics & Development 2016, 38:90–96 References and recommended reading
Papers of particular interest, published within the period of review,
have been highlighted as:
 of special interest
 of outstanding interest
1. Querfurth HW, LaFerla FM: Alzheimer’s disease. N Eng J Med
2010, 362:329-344.
2. Armstrong RA, Lantos PL, Cairns NJ: What determines the
molecular composition of abnormal protein aggregates in
neurodegenerative disease? Neuropathology 2008, 28:351-
365.
3. Atwood CS, Martins RN, Smith MA, Perry G: Senile plaque
composition and posttranslational modification of amyloid-
b peptide and associated proteins. Peptides 2002, 23:1343-
1350.
4. Selkoe DJ: Alzheimer’s disease. Cold Spring Harb Perspect Biol
2011, 3:a004457.
5. Holtzman DM, Herz J, Bu G: Apolipoprotein E and
apolipoprotein E receptors: normal biology and roles in
Alzheimer disease. Cold Spring Harb Perspect Biol 2012,
2:a006312.
6. Huang Y: Ab-independent roles of apolipoprotein E4 in the
pathogenesis of Alzheimer’s disease. Trends Mol Med 2010,
16:287-294.
7. Hardy JA, Higgins GA: Alzheimer’s disease: the amyloid
cascade hypothesis. Science 1992, 256:184-185.
8. Schon EA, Area-Gomez E: Is Alzheimer’s disease a disorder of
mitochondria-associated membranes? J Alzheimers Dis 2010,
20:S281-S292.
9. Schon EA, Area-Gomez E: Mitochondria-associated E.R.
membranes in Alzheimer disease. Mol Cell Neurosci 2013,
55:26-36.
10. Stefani M, Liguri G: Cholesterol in Alzheimer’s disease:
unresolved questions. Curr Alzheimer Res 2009, 6:15-29.
11. Fraser T, Tayler H, Love S: Fatty acid composition of frontal,
temporal and parietal neocortex in the normal human brain
and in Alzheimer’s disease. Neurochem Res 2010, 35:503-513.
12. Hoyer S, Oesterreich K, Wagner O: Glucose metabolism as the
site of the primary abnormality in early-onset dementia of
Alzheimer type? J Neurol 1988, 235:143-148.
13. Liu F, Shi J, Tanimukai H, Gu J, Gu J, Grundke-Iqbal I, Iqbal K,
Gong CX: Reduced O-GlcNAcylation links lower brain glucose
metabolism and tau pathology in Alzheimer’s disease. Brain
2009, 132:1820-1832.
14. Pettegrew JW, Panchalingam K, Hamilton RL, McClure RJ: Brain
membrane phospholipid alterations in Alzheimer’s disease.
Neurochem Res 2001, 26:771-782.
15. Bezprozvanny I, Mattson MP: Neuronal calcium mishandling
and the pathogenesis of Alzheimer’s disease. Trends Neurosci
2008, 31:454-463.
16. Wang X, Su B, Zheng L, Perry G, Smith MA, Zhu X: The role of
abnormal mitochondrial dynamics in the pathogenesis of
Alzheimer’s disease. J Neurochem 2009, 109:153-159.
17. Area-Gomez E, Schon EA: Mitochondrial genetics and disease.
J Child Neurol 2014, 29:1208-1215.
18.

Csordas G, Renken C, Varnai P, Walter L, Weaver D, Buttle KF,
Balla T, Mannella CA, Hajnoczky G: Structural and functional
features and significance of the physical linkage between ER
and mitochondria. J Cell Biol 2006, 174:915-921.
This paper, along with a follow-on paper in 2010 (Ref [40]), provided some
of the key structural, morphological, and biochemical data supporting the
physical and biochemical connectivity between ER and mitochondria at
the MAM, focusing on the transfer of calcium between the two organelles.
19.

Hayashi T, Rizzuto R, Hajnoczky G, Su TP: MAM: more than just a
housekeeper. Trends Cell Biol 2009, 19:81-88.
An excellent review of MAM structure and function.www.sciencedirect.com
Mitochondria-associated ER membranes and Alzheimer disease Area-Gomez and Schon 9520. Raturi A, Simmen T: Where the endoplasmic reticulum and the
mitochondrion tie the knot: the mitochondria-associated
membrane (MAM). Biochim Biophys Acta 2013, 1833:213-224.
21. Rusinol AE, Cui Z, Chen MH, Vance JE: A unique mitochondria-
associated membrane fraction from rat liver has a high
capacity for lipid synthesis and contains pre-Golgi secretory
proteins including nascent lipoproteins. J Biol Chem 1994,
269:27494-27502.
22. Vance DE, Walkey CJ, Cui Z: Phosphatidylethanolamine N-
methyltransferase from liver. Biochim Biophys Acta 1997,
1348:142-150.
23. Stone SJ, Vance JE: Phosphatidylserine synthase-1 and -2 are
localized to mitochondria-associated membranes. J Biol Chem
2000, 275:34534-34540.
24. Prasad M, Kaur J, Pawlak KJ, Bose M, Whittal RM, Bose HS:
Mitochondria-associated endoplasmic reticulum membrane
(MAM) regulates steroidogenic activity via steroidogenic
acute regulatory protein (StAR)-voltage-dependent anion
channel 2 (VDAC2) interaction. J Biol Chem 2015, 290:2604-
2616.
25. Mendes CC, Gomes DA, Thompson M, Souto NC, Goes TS,
Goes AM, Rodrigues MA, Gomez MV, Nathanson MH, Leite MF:
The type III inositol 1,4,5-trisphosphate receptor preferentially
transmits apoptotic Ca2+ signals into mitochondria. J Biol
Chem 2005, 280:40892-40900.
26. Szabadkai G, Bianchi K, Varnai P, De Stefani D, Wieckowski MR,
Cavagna D, Nagy AI, Balla T, Rizzuto R: Chaperone-mediated
coupling of endoplasmic reticulum and mitochondrial Ca2+
channels. J Cell Biol 2006, 175:901-911.
27. Jia W, Moulson CL, Pei Z, Miner JH, Watkins PA: Fatty acid
transport protein 4 is the principal very long chain fatty acyl-
CoA synthetase in skin fibroblasts. J Biol Chem 2007,
282:20573-20583.
28. Friedman JR, Lackner LL, West M, DiBenedetto JR, Nunnari J,
Voeltz GK: ER tubules mark sites of mitochondrial division.
Science 2011, 334:358-362.
29. de Brito OM, Scorrano L: Mitofusin 2 tethers endoplasmic
reticulum to mitochondria. Nature 2008, 456:605-610.
30.

Simmen T, Aslan JE, Blagoveshchenskaya AD, Thomas L, Wan L,
Xiang Y, Feliciangeli SF, Hung CH, Crump CM, Thomas G: PACS-2
controls endoplasmic reticulum–mitochondria
communication and Bid-mediated apoptosis. EMBO J 2005,
24:717-729.
The study was among the first to identify a specific protein — PACS2 —
that regulates ER–mitochondral apposition in mammalian cells, including
an unexpected relationship of this apposition to apoptosis, via tBID.
31.

Area-Gomez E, de Groof AJ, Boldogh I, Bird TD, Gibson GE,
Koehler CM, Yu WH, Duff KE, Yaffe MP, Pon LA et al.: Presenilins
are enriched in endoplasmic reticulum membranes
associated with mitochondria. Am J Pathol 2009, 175:1810-
1816.
This was the first paper to report the enrichment of presenilins and g-
secretase activity in the MAM subdomain of the ER.
32. Newman M, Wilson L, Verdile G, Lim A, Khan I, Moussavi Nik SH,
Pursglove S, Chapman G, Martins RN, Lardelli M: Differential,
dominant activation and inhibition of Notch signalling and APP
cleavage by truncations of PSEN1 in human disease. Hum Mol
Genet 2014, 23:602-617.
33. Schreiner B, Hedskog L, Wiehager B, Ankarcrona M: Amyloid-b
peptides are generated in mitochondria-associated
endoplasmic reticulum membranes. J Alzheimers Dis 2015,
43:369-374.
34. Du H, Guo L, Fang F, Chen D, Sosunov AA, McKhann GM, Yan Y,
Wang C, Zhang H, Molkentin JD et al.: Cyclophilin D deficiency
attenuates mitochondrial and neuronal perturbation and
ameliorates learning and memory in Alzheimer’s disease. Nat
Med 2008, 14:1097-1105.
35. Hansson CA, Frykman S, Farmery MR, Tjernberg LO, Nilsberth C,
Pursglove SE, Ito A, Winblad B, Cowburn RF, Thyberg J et al.:
Nicastrin, presenilin, APH-1, and PEN-2 form activewww.sciencedirect.com g-secretase complexes in mitochondria. J Biol Chem 2004,
279:51654-51660.
36.

Area-Gomez E, Del Carmen Lara Castillo M, Tambini MD, Guardia-
Laguarta C, de Groof AJC, Madra M, Ikenouchi J, Umeda M,
Bird TD, Sturley SL et al.: Upregulated function of mitochondria-
associated ER membranes in Alzheimer disease. EMBO J
2012, 31:4106-4123.
This paper analyzed the role of MAM in the pathogenesis of AD. It showed
that ER–mitochondrial apposition is increased massively in presenilin-
mutant and AD cells, and that MAM function (e.g. cholesteryl ester
synthesis; phospholipid transfer) is increased as well. It proposed that
many of the phenotypes of AD could be explained by perturbed MAM
structure and function.
37.

Hayashi T, Fujimoto M: Detergent-resistant microdomains
determine the localization of sigma-1 receptors to the
endoplasmic reticulum–mitochondria junction. Mol Pharmacol
2010, 77:517-528.
One of the first papers to identify MAM as an intracellular lipid raft-like
domain. This finding helped resolve the paradox of the intracellular
localization of presenilins and g-secretase activity to rafts, which had
been thought by many to be present only at the plasma membrane.
38. Vetrivel KS, Cheng H, Lin W, Sakurai T, Li T, Nukina N, Wong PC,
Xu H, Thinakaran G: Association of g-secretase with lipid rafts
in post-Golgi and endosome membranes. J Biol Chem 2004,
279:44945-44954.
39. Marambaud P, Shioi J, Serban G, Georgakopoulos A, Sarner S,
Nagy V, Baki L, Wen P, Efthimiopoulos S, Shao Z et al.: A
presenilin-1/g-secretase cleavage releases the E-cadherin
intracellular domain and regulates disassembly of adherens
junctions. EMBO J 2002, 21:1948-1956.
40. Csordas G, Varnai P, Golenar T, Roy S, Purkins G, Schneider TG,
Balla T, Hajnoczky G: Imaging interorganelle contacts and local
calcium dynamics at the ER–mitochondrial interface. Mol Cell
2010, 39:121-132.
41. Patergnani S, Suski JM, Agnoletto C, Bononi A, Bonora M, De
Marchi E, Giorgi C, Marchi S, Missiroli S, Poletti F et al.: Calcium
signaling around mitochondria associated membranes
(MAMs). Cell Commun Signal 2011, 9:19.
42. Liang J, Kulasiri D, Samarasinghe S: Ca2+ dysregulation in the
endoplasmic reticulum related to Alzheimer’s disease: a
review on experimental progress and computational
modeling. Biosystems 2015, 134:1-15.
43. Mattson MP: ER calcium and Alzheimer’s disease: in a state of
flux. Sci Signal 2010, 3:pe10.
44. Supnet C, Bezprozvanny I: Neuronal calcium signaling,
mitochondrial dysfunction, and Alzheimer’s disease. J
Alzheimers Dis 2010, 20(Suppl 2):S487-S498.
45. Gibson GE, Vestling M, Zhang H, Szolosi S, Alkon D, Lannfelt L,
Gandy S, Cowburn RF: Abnormalities in Alzheimer’s disease
fibroblasts bearing the APP670/671 mutation. Neurobiol Aging
1997, 18:573-580.
46. Peterson C, Goldman JE: Alterations in calcium content and
biochemical processes in cultured skin fibroblasts from aged
and Alzheimer donors. Proc Natl Acad Sci U S A 1986, 83:2758-
2762.
47. Sims NR, Finegan JM, Blass JP: Altered metabolic properties of
cultured skin fibroblasts in Alzheimer’s disease. Ann Neurol
1987, 21:451-457.
48. Sun S, Zhang H, Liu J, Popugaeva E, Xu N-J, Feske S, White CL III,
Bezprozvanny I: Reduced synaptic STIM2 expression and
impaired store-operated calcium entry cause destabilization
of mature spines in mutant presenilin mice. Neuron 2014,
82:79-93.
49. Cho D-H, Nakamura T, Fang J, Cieplak P, Godzik A, Gu Z,
Lipton SA: S-nitrosylation of Drp1 mediates b-amyloid-related
mitochondrial fission and neuronal injury. Science 2009,
324:102-105.
50. Ferrer I: Altered mitochondria, energy metabolism, voltage-
dependent anion channel, and lipid rafts converge to exhaust
neurons in Alzheimer’s disease. J Bioenerg Biomembr 2009,
41:425-431.Current Opinion in Genetics & Development 2016, 38:90–96
96 Molecular and genetic bases of disease51. Gibson GE, Huang H-M: Mitochondrial enzymes and
endoplasmic reticulum calcium stores as targets of oxidative
stress in neurodegenerative diseases. J Bioenerg Biomembr
2004, 36:335-340.
52. Riemer J, Kins S: Axonal transport and mitochondrial
dysfunction in Alzheimer’s disease. Neurodegener Dis 2013,
12:111-124.
53. Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E,
Mount SL, Raman R, Davies P, Masliah E, Williams DS et al.:
Axonopathy and transport deficits early in the pathogenesis of
Alzheimer’s disease. Science 2005, 307:1282-1288.
54. Wang X, Su B, Siedlak SL, Moreira PI, Fujioka H, Wang Y,
Casadesus G, Zhu X: Amyloid-b overproduction causes
abnormal mitochondrial dynamics via differential modulation
of mitochondrial fission/fusion proteins. Proc Natl Acad Sci U S
A 2008, 105:19318-19323.
55. Young-Collier KJ, McArdle M, Bennett JP: The dying of the light:
mitochondrial failure in Alzheimer’s disease. J Alzheimers Dis
2012, 28:771-781.
56. Flis VV, Daum G: Lipid transport between the endoplasmic
reticulum and mitochondria. Cold Spring Harb Perspect Biol
2013, 5:a013235.
57. Voelker DR: Bridging gaps in phospholipid transport. Trends
Biochem Sci 2005, 30:396-404.
58. Puglielli L, Konopka G, Pack-Chung E, Ingano LA, Berezovska O,
Hyman BT, Chang TY, Tanzi RE, Kovacs DM: Acyl-coenzyme
A:cholesterol acyltransferase modulates the generation of the
amyloid b-peptide. Nat Cell Biol 2001, 3:905-912.
59. Feng B, Yao PM, Li Y, Devlin CM, Zhang D, Harding HP,
Sweeney M, Rong JX, Kuriakose G, Fisher EA et al.: The
endoplasmic reticulum is the site of cholesterol-induced
cytotoxicity in macrophages. Nat Cell Biol 2003, 5:781-792.
60. Go´mez-Ramos P, Asuncio´n Mora´n M: Ultrastructural
localization of intraneuronal Ab-peptide in Alzheimer disease
brains. J Alzheimers Dis 2007, 11:53-59.
61. Pani A, Dessı` S, Diaz G, La Colla P, Abete C, Mulas C, Angius F,
Cannas MD, Orru CD, Cocco PL et al.: Altered cholesterol ester
cycle in skin fibroblasts from patients with Alzheimer’s
disease. J Alzheimers Dis 2009, 18:829-841.
62.

Puglielli L, Ellis BC, Ingano LA, Kovacs DM: Role of acyl-
coenzyme A:cholesterol acyltransferase activity in the
processing of the amyloid precursor protein. J Mol Neurosci
2004, 24:93-96.
Together with a previous report in 2001 (Ref [58]), this paper made the
remarkable observation that ablation of ACAT1, an enzyme required forCurrent Opinion in Genetics & Development 2016, 38:90–96 the intra-cellular esterification of cholesterol (and which is enriched in the
MAM), is required for the production of Ab.
63.

Tambini MD, Pera M, Kanter E, Yang H, Guardia-Laguarta C,
Holtzman D, Sulzer D, Area-Gomez E, Schon EA: ApoE4
upregulates the activity of mitochondria-associated ER
membranes. EMBO Rep 2016, 17:27-36.
This paper showed that the e4 allele of APOE, the greatest biochemical
risk factor for developing sporadic AD, affects MAM function preferen-
tially to the e3 allele. As such, it provides support for the MAM hypothesis.
64. Heeren J, Grewal T, Laatsch A, Rottke D, Rinninger F, Enrich C,
Beisiegel U: Recycling of apoprotein E is associated with
cholesterol efflux and high density lipoprotein internalization.
J Biol Chem 2003, 278:14370-14378.
65. Heeren J, Grewal T, Laatsch A, Becker N, Rinninger F, Rye K-A,
Beisiegel U: Impaired recycling of apolipoprotein E4 is
associated with intracellular cholesterol accumulation. J Biol
Chem 2004, 279:55483-55492.
66. Ikonen E: Cellular cholesterol trafficking and
compartmentalization. Nat Rev Mol Cell Biol 2008, 9:125-138.
67. Wollmer MA: Cholesterol-related genes in Alzheimer’s disease.
Biochim Biophys Acta 2010, 1801:762-773.
68. Steinberg S, Stefansson H, Jonsson T, Johannsdottir H,
Ingason A, Helgason H, Sulem P, Magnusson OT, Gudjonsson SA,
Unnsteinsdottir U et al.: Loss-of-function variants in ABCA7
confer risk of Alzheimer’s disease. Nat Genet 2015, 47:445-447.
69. Abe-Dohmae S, Ikeda Y, Matsuo M, Hayashi M, Okuhira K-i,
Ueda K, Yokoyama S: Human ABCA7 supports apolipoprotein-
mediated release of cellular cholesterol and phospholipid to
generate high density lipoprotein. J Biol Chem 2004, 279:604-
611.
70.

Winkler E, Kamp F, Scheuring J, Ebke A, Fukumori A, Steiner H:
Generation of Alzheimer disease-associated amyloid b42/43
peptide by g-secretase can be inhibited directly by
modulation of membrane thickness. J Biol Chem 2012,
287:21326-21334.
This paper describes a mechanism for increasing the Ab42:Ab40 ratio,
based more on the biophysical properties of the membrane in which g-
secretase resides than on any particular defect in the enzyme or its
substrate.
71. Perl DP: Neuropathology of Alzheimer’s disease. Mt Sinai J Med
2010, 77:32-42.
72. Yoshikane H, Nihei T, Moriyama K: Three-dimensional
observation of intracellular membranous structures in dog
heart muscle cells by scanning electron microscopy. J
Submicrosc Cytol 1986, 18:629-636.www.sciencedirect.com
